|
|
Home
Search
Study Topics
Glossary
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||
| Sponsored by: |
National Institute on Drug Abuse (NIDA) |
|---|---|
| Information provided by: | National Institute on Drug Abuse (NIDA) |
| ClinicalTrials.gov Identifier: | NCT00000300 |
Purpose
The purpose of this study is to test therapeutic benefits of take-home LAAM. (1) Do subjects with take-home LAAM availability show increased clinical responsibility over subjects without; (2) Do subjects with take-home LAAM attempt diversion when random recall and other diversion safeguards are used; (3) Does treatment response correlate with background or drug use variables at intake, discharge, or during treatment?
| Condition | Intervention | Phase |
|---|---|---|
|
Opioid-Related Disorders |
Drug: LAAM |
Phase IV |
| Study Type: | Interventional |
| Study Design: | Treatment, Randomized |
| Official Title: | Feasibility Study of Take-Home LAAM Medication |
| Estimated Enrollment: | 0 |
| Study Start Date: | March 1995 |
1-Year study, participant will be randomly assigned to one of two groups: One will have the opportunity to earn take-home doses by turning in a designated number of clean urines. Two will not have the opportunity to earn take-home doses. Clinic visits three times per week. Urine sample given at each visit.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
meets DSM-IV criteria for opiate dependence. M/F, 18 years or older. Certified for LAAm treatment by a physician. Able to understand english. Willing to provide names, addresses, and numbers of 3 relatives who can aid in patient location for follow-up visits.
Exclusion Criteria:
Hypertensive to LAAM. Pregnant or nursing women. Female of childbearing potential who refuses to use an acceptable form of birth control. Clinically significant abnormality in hematology, blood work, or UA, ETOH and/or sedative/hypnotic dependence according to DSM-IV criteria. Medical or psychiatric illness which would jeopardize safe study participation.
Contacts and Locations| United States, California | |
| Friends Research Institute | |
| Los Angeles, California, United States, 90025 | |
| Principal Investigator: | Walter Ling, M.D. | Friends Research Institute, Inc. |
More Information
| Study ID Numbers: | NIDA-09260-3, P50-09260-3 |
| Study First Received: | September 20, 1999 |
| Last Updated: | November 3, 2005 |
| ClinicalTrials.gov Identifier: | NCT00000300 |
| Health Authority: | United States: Federal Government |
|
Mental Disorders Substance-Related Disorders Disorders of Environmental Origin Opioid-Related Disorders |
